Abstract
Clinical trials performed for new therapeutic agents approval, are based on heavily selected patients. Efficacy and toxicity profiles can be difficult to confirm in daily practice. Real-world data on this therapy are necessary to evaluate the generalizability of the trials results, to the general lung cancer patients population. These data can also identify other patients characteristics associated with poor outcomes or with good response rates. In this revue, we’ll report the main data, published or shown in major oncologic congress, regarding the results in the entire population, and in specific sub groups of patients (PS2, elderly, brain mets...).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
